MHR
NBIX icon

Matthew Hamilton Rosenberg’s Neurocrine Biosciences NBIX Stock Holding History

Matthew Hamilton Rosenberg’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-4
Closed -$461 – 843
2024
Q3 		$461 Hold
4
– – ﹤0.01% 801
2024
Q2 		$560 Hold
4
– – ﹤0.01% 760
2024
Q1 		$566 Hold
4
– – ﹤0.01% 798
2023
Q4 		$527 Hold
4
– – ﹤0.01% 822
2023
Q3 		$450 Hold
4
– – ﹤0.01% 826
2023
Q2 		$377 Hold
4
– – ﹤0.01% 857
2023
Q1 		$405 Hold
4
– – ﹤0.01% 887
2022
Q4 		$478 Buy
+4
New +$469 ﹤0.01% 873

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Matthew Hamilton Rosenberg's NBIX Position: Q4 2024 in Review

Matthew Hamilton Rosenberg sold out of Neurocrine Biosciences (NBIX) in Q4 2024, closing a stake of 4 shares — an estimated $461 sold.

Matthew Hamilton Rosenberg first reported a position in NBIX in Q4 2022 and held it in 8 quarters. The position peaked at $566 in Q1 2024. 600 funds tracked by Wall St. Rank hold NBIX as of Q4 2024.

  • Matthew Hamilton Rosenberg reported no remaining Neurocrine Biosciences position as of Q4 2024 after selling out during the quarter.
  • Matthew Hamilton Rosenberg sold 4 Neurocrine Biosciences shares in Q4 2024, an estimated $461.
  • Matthew Hamilton Rosenberg first reported a position in Neurocrine Biosciences in Q4 2022 and held it in 8 quarters.
  • Matthew Hamilton Rosenberg's Neurocrine Biosciences position peaked at $566 in Q1 2024.
  • 600 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q4 2024.

Based on Matthew Hamilton Rosenberg's 13F filing for Q4 2024, filed 14 Jan 2025.